FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to
Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(b)

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL OMB Number: Estimated average burden hours per response: 0.5

X 10% Owner

Other (specify below)

7. Nature of

Beneficial Ownership

Footnote⁽²⁾

11. Nature

of Indirect

Beneficial

Ownership (Instr. 4)

(Instr. 4)

See

Indirect

5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

6. Individual or Joint/Group Filing (Check Applicable Line)

Form filed by One Reporting Person Form filed by More than One Reporting

6. Ownership

Form: Direct

(D) or Indirect (I) (Instr. 4)

Ι

10.

Form: Direct (D) or Indirect (I) (Instr. 4)

Ownership

Director

5. Amount of

Beneficially Owned Following

18,088,597

9. Number of

derivative Securities

Beneficially Owned

Following

Reported Transaction(s) (Instr. 4)

Reported Transaction(s) (Instr. 3 and 4)

Officer (give title

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 Investment Company Act of 1940

	(-)				(or Se	ection	30(h)) of th	e Inve	estme	nt C	Company Act	of 1940				
						2. Issuer Name and Ticker or Trading Symbol <u>AMICUS THERAPEUTICS INC</u> [FOLD]									5. Relationship o (Check all applic Director			
(Last) (First) (Middle) 51 ASTOR PLACE, 10TH FLOOR						3. Date of Earliest Transaction (Month/Day/Year) 03/02/2018									Officer (below)			
-					- 4	I. If A	men	dmen	t, Dat	e of C	Origina	ıl Fil	ed (Month/Da	ay/Year)			dividual o	or J
(Street) NEW YO	ORK N	Υ 1	10003	ŀ												Line) Form fil		
(City)			Zip)		-											2	Forr Pers	
	<u> </u>			Non-Deriv	vativ	ve S	Sec	uritio	es A	cau	ired	. D	isposed o	f. or E	3enefi	ciall	v Own	ed
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Ye				ion	Execution Da				3. Transaction Code (Instr. 8)			4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and				Beneficial Owned Fo		
								Cod	Code V		Amount	(A) or (D) Price		Reported Transactio (Instr. 3 ar				
Common	Stock			03/02/20	018				P				100,000	A	\$13.8	395 ⁽¹⁾	18,0	88
		Та	ıble I										oosed of,				Owned	
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	Execu	eemed ution Date, , th/Day/Year)		nsact de (In:		of Deri Secu Acqu (A) o Disp of (D	osed) r. 3, 4	e (M	Date E opiration	on D		7. Title Amour Securi Under Deriva Securi and 4)	nt of ties lying	D S (I	8. Price of Derivative Security (Instr. 5)	
					Cod	de V	<i>,</i>	(A)	(D)		ate kercisa	able	Expiration Date	Title	Amoun or Numbe of Shares	er		
		Reporting Person*	LC												•			
(Last) 51 ASTO	OR PLACE,	(First) 10TH FLOOR	(Middle)														
(Street) NEW YO	ORK	NY	1	10003			-											
(City)		(State)	(Zip)														
	EPTIVE L	Reporting Person*	ES I	MASTEI	<u>R</u>													
(Last) 51 AST	OR PLACE,	(First) 10TH FLOOR	(Middle)			-											
(Street) NEW Y	ORK	NY	1	10003			-											
(City)		(State)	(Zip)														
ı	nd Address of	Reporting Person*																
(Last) 51 ASTO	OR PLACE.	(First) 10TH FLOOR	(Middle)														

(Street) NEW YORK	NY	10003				
(City)	(State)	(Zip)				

Explanation of Responses:

1. The transaction was executed in multiple trades at prices ranging from \$13.725 to \$14.00. The price above reflects the weighted average price. Detailed information regarding the number of shares transacted at each separate price will be provided upon request by the Commission staff, the Issuer or a security holder of the Issuer.

2. The securities are directly held by Perceptive Life Sciences Master Fund Ltd. (the "Master Fund"). Perceptive Advisors LLC (the "Advisor") serves as the investment manager of Master Fund. Joseph Edelman is the managing member of the Advisor. Each of Mr. Edelman and the Advisor disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein, and this report shall not be deemed an admission that either Mr. Edelman or the Advisor is the beneficial owner of such securities for purposes of Section 16 or for any other purposes.

Remarks:

/s/ Jospeh Edelman - for
Perceptive Life Sciences
Master Fund Ltd., By:
Perceptive Advisors LLC, its
investment manager, By:
Joseph Edelman, its managing
member
/s/ Jospeh Edelman - for

Perceptive Advisors LLC, By:
Joseph Edelman, its managing
03/06/2018

nember

<u>/s/ Joseph Edelman</u> <u>03/06/2018</u>
** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.